[{"id":"789ee0d1-aea7-4d2b-936c-5e9fea45fbe0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06730100","created_at":"2025-02-26T09:55:55.597Z","updated_at":"2025-02-26T09:55:55.597Z","phase":"Phase 2","brief_title":"CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer","source_id_and_acronym":"NCT06730100","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" SLFN11","pipe":"","alterations":" ","tags":["SLFN11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alphalex-exatecan (CBX-12)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 05/23/2025","start_date":" 05/23/2025","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-12-12"},{"id":"f269309d-3a63-4270-8476-61faefe6970a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05691517","created_at":"2023-01-20T16:00:14.301Z","updated_at":"2024-07-02T16:35:03.683Z","phase":"Phase 1","brief_title":"Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers","source_id_and_acronym":"NCT05691517","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" RAD51","pipe":"","alterations":" ","tags":["RAD51"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alphalex-exatecan (CBX-12)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/13/2025","start_date":" 01/13/2025","primary_txt":" Primary completion: 10/15/2026","primary_completion_date":" 10/15/2026","study_txt":" Completion: 10/15/2026","study_completion_date":" 10/15/2026","last_update_posted":"2024-05-14"}]